Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Hypertension

    Olathe, KS

    Search
    Hypertension
    Olathe, KS
    Show Map
    Map View
    Olathe, KS
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      66 Hypertension Trials near Olathe, KS

      Power is an online platform that helps thousands of Hypertension patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Sotatercept for Pulmonary Arterial Hypertension

      Kansas City, Kansas
      Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial. * About the safety of sotatercept and if people tolerate it
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Coronary Artery Disease, Obstructive Sleep Apnea, Others

      160 Participants Needed

      LTP001 for Pulmonary Arterial Hypertension

      Kansas City, Kansas
      A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Cardiac Abnormalities, Hypersensitivity, Others
      Must Be Taking:PAH Therapies

      232 Participants Needed

      AGN-193408 SR for Glaucoma

      Kansas City, Missouri
      This trial is testing a new medication called AGN-193408 SR to see if it can safely lower eye pressure in people with open-angle glaucoma or ocular hypertension.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Ocular Trauma, Herpetic Ocular Diseases, Others
      Must Not Be Taking:Corticosteroids

      96 Participants Needed

      Vicadrostat + Empagliflozin for Type 2 Diabetes and Hypertension

      Kansas City, Missouri
      This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Atrial Fibrillation, Others
      Must Be Taking:Antihypertensives, Antidiabetics, Cardiovascular Drugs

      11800 Participants Needed

      QCZ484 for High Blood Pressure

      Kansas City, Missouri
      The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Secondary Hypertension, Hepatic Disease, CHF, Others
      Must Not Be Taking:RAAS Inhibitors, ACEi, ARBs

      380 Participants Needed

      Milrinone for Congenital Diaphragmatic Hernia

      Kansas City, Missouri
      This trial is testing if milrinone, a medicine that helps the heart and lungs, can improve oxygen levels in newborns with severe lung and heart problems due to CDH. These babies often don't get better with usual treatments. The goal is to see if milrinone can safely help these babies breathe easier. Milrinone is used in up to 30% of CDH infants across the United States, but no studies have tested its effectiveness or safety in these newborns.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:0+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      66 Participants Needed

      Mechanical Circulatory Support for Heart Failure

      Kansas City, Missouri
      The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Inotrope Use, Thyroid Disease, Valvular Heart Disease, Others
      Must Be Taking:Betablockers, ACE Inhibitors, Diuretics, SGLT2 Inhibitors

      850 Participants Needed

      Mosliciguat for Pulmonary Hypertension

      Kansas City, Kansas
      This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:PH Group 1, 2, 4, 5, Others
      Must Not Be Taking:Mosliciguat, SGC Stimulators

      120 Participants Needed

      Baxdrostat + Dapagliflozin for Chronic Kidney Disease and High Blood Pressure

      Kansas City, Missouri
      International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:T1DM, Uncontrolled T2DM, Heart Failure, Others
      Must Be Taking:ACEi, ARB

      5000 Participants Needed

      Baxdrostat + Dapagliflozin for Chronic Kidney Disease

      Kansas City, Missouri
      The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone. Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 6-weeks (approximately), where reassessment of GFR will occur for the primary efficacy endpoint. In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Diabetes, Heart Failure, Others
      Must Be Taking:ACE Inhibitors, ARBs

      2455 Participants Needed

      Inclisiran for Cardiovascular Disease Prevention

      Kansas, Missouri
      This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40 - 79

      Key Eligibility Criteria

      Disqualifiers:ASCVD, Revascularization, Liver Disease, Others
      Must Be Taking:Lipid Lowering

      14012 Participants Needed

      Belapectin for NASH Cirrhosis

      Kansas City, Missouri
      This trial is testing belapectin, a medication aimed at helping people with a severe liver condition called NASH cirrhosis. The study focuses on patients who have high blood pressure in their liver but no swollen veins in their esophagus. Belapectin works by reducing liver inflammation and scarring, which can improve liver function and reduce health problems.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Alcohol Abuse, Drug Abuse, HIV, Others
      Must Not Be Taking:Non-selective Beta Blockers

      357 Participants Needed

      Bimatoprost SR for Glaucoma

      Kansas City, Missouri
      This trial tests a long-lasting eye medication called Bimatoprost SR. It is for people with certain eye conditions who can't use regular eye drops effectively. The medication works by helping fluid drain from the eye, reducing pressure. Bimatoprost has been widely used for glaucoma management, typically delivered via eye drops, but newer methods like sustained-release implants are being explored to improve efficiency.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Concurrent Study, Previous Bimatoprost SR

      515 Participants Needed

      Baxdrostat for High Blood Pressure

      Kansas City, Missouri
      This trial tests Baxdrostat, a pill taken regularly, in adults with high blood pressure that isn't controlled by their current medications. Baxdrostat works by lowering the force of blood against artery walls.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Atrial Fibrillation, Others
      Must Be Taking:Diuretics, Antihypertensives

      796 Participants Needed

      Reformulated PG324 for Glaucoma

      Pittsburg, Kansas
      This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Intraocular Pressure > 36 MmHg, Others
      Must Be Taking:Ocular Hypotensives

      470 Participants Needed

      Zilebesiran for High Blood Pressure

      El Dorado, Kansas
      The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Secondary Hypertension, Orthostatic Hypotension, Others
      Must Be Taking:Antihypertensives

      375 Participants Needed

      Enhanced COACH CDS Tool for High Blood Pressure

      Columbia, Missouri
      Hypertension is a significant contributor to poor cardiovascular outcomes. Self-management support tools can increase patient behaviors to improve blood pressure. The investigators created a clinical decision support app, called COACH, to integrate home blood pressure data and goals into EHR reporting and workflow with communications informed by behavioral economics principles to support shared decision-making. The study aims to measure the effectiveness of the COACH intervention in a pragmatic multi-site randomized trial in a primary care setting.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cognitive Impairment, Hospice, Others

      550 Participants Needed

      Dapagliflozin + Baxdrostat for Chronic Kidney Disease

      Wichita, Kansas
      International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
      Prior Safety Data

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Diabetes, Heart Failure, Others
      Must Be Taking:ACE Inhibitors, ARBs

      218 Participants Needed

      Timolol + Latanoprost for Glaucoma

      Omaha, Nebraska
      Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to medications is a critical barrier for the clinician to consistently provide highly effective IOP-based treatments. Current trial-and-error approaches to glaucoma management are inefficient and have not addressed this barrier as there are no predictive factors for drug response. Our long-term goal is to improve outcomes by identifying biomarkers and environmental factors that profile a patient at risk for glaucoma by age-of-onset, rate of disease progression, "poor response" to treatment, and large IOP fluctuation. Our purpose of this research project is to address this critical barrier by focusing on physiological factors that predict IOP response to drugs.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Advanced Visual Loss, Others
      Must Not Be Taking:Cannabis, Lumify, Latisse, Steroids

      100 Participants Needed

      Renal Denervation for High Blood Pressure

      Omaha, Nebraska
      This trial is studying the safety and effectiveness of a device called the Symplicity Spyral system, which helps lower blood pressure by calming overactive nerves in the kidneys. It includes patients who have already received this treatment. The Symplicity Spyral system is part of a series of treatments, with earlier versions showing significant blood pressure reductions in patients with resistant hypertension.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Renal Anatomy, Oxygen Support, Diabetes, Others

      1300 Participants Needed

      Why Other Patients Applied

      "I have a known blockage developing in lower left main 50%, which my doctors are watching. We've considered surgery, but I'd like to rule out all possible other options first. I've done some research, which brought me to clinical trials."

      PA
      Artery Disease PatientAge: 64

      "I have gasteroparesis which causes me extreme bloating, pain, acid reflux, occasional vomiting, nausea, and constipation. Most standard medications have not helped. I did some research to learn about investigational drugs, which I'd be excited to get to access through a trial."

      BW
      Gasteroparesis PatientAge: 38

      "My ejection fraction is now 20-25%, quite low. Trying to optimize my medications at this time. I have had Biventricular pacemaker/ICD since 2007. I am doing everything I can to improve my health. Following a diet, exercising 30 minutes every day. Most days my systolic blood pressure is < 100. I had a L/R Cath in December and do not have any problems with my coronary arteries. I'm hoping to learn more about the latest research and drugs by participating in a trial. "

      WB
      Heart Failure PatientAge: 66

      "In December 2023 I had a stent placed in an artery. I was so glad that the blockage was found before I had either a heart attack, stroke, or both. I have been on Pravastatin for as long as I can remember but I continue to have elevated cholesterol levels. I'm trying to get ahead of my condition by learning more about the latest research and drugs available."

      AQ
      Hypercholesterolemia PatientAge: 57

      "I've been diagnosed with type 2 diabetes since 2000. I was on the highest dose of metformin, which didn't work for me. In 2022, I tried Ozempic, which had bad side effects. I'm not currently on anything to treat my diabetes, given my experiences (as well as some insurance denials). I'm glad that clinical trials exist to help me try to access the latest research. I'm frustrated but also motivated."

      PL
      Diabetes PatientAge: 53
      Match to a Hypertension Trial

      Lorundrostat for High Blood Pressure

      Omaha, Nebraska
      This trial tests lorundrostat, a drug that lowers blood pressure by blocking a hormone that makes the body hold onto salt and water. It targets patients whose high blood pressure isn't controlled by standard treatments.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      285 Participants Needed

      Sotatercept for Pulmonary Hypertension

      Omaha, Nebraska
      Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF). Researchers want to know if the study treatment, sotatercept, can treat people with Cpc-PH caused by HFpEF. This is an extension study, which means people who took part in a certain study on sotatercept for Cpc-PH (called a parent study) may be able to join this study. In this extension study, people will take sotatercept and researchers will follow their health for a longer time. The main goal of this extension study is to learn about the long-term safety of sotatercept and if people tolerate it over a longer period of time.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Liver Disease, Pregnancy, Others

      130 Participants Needed

      TX000045 for Pulmonary Hypertension

      Omaha, Nebraska
      TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Significant Lung Disease, Cardiovascular, Others
      Must Not Be Taking:Vasoactive Drugs

      180 Participants Needed

      AI Device for Pulmonary Hypertension in Interstitial Lung Disease

      Omaha, Nebraska
      MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Low Ejection Fraction, Others
      Must Not Be Taking:Pulmonary Hypertension Therapies

      1000 Participants Needed

      Ralinepag for Pulmonary Arterial Hypertension

      Omaha, Nebraska
      This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Severe Liver Disease, Renal Insufficiency, Malignancy, Others
      Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors

      1000 Participants Needed

      Ralinepag for Pulmonary Arterial Hypertension

      Omaha, Nebraska
      This trial tests ralinepag, a medication for lung disease, on patients with PAH who participated in earlier research. It aims to improve blood flow in the lungs by relaxing blood vessels and reducing pressure.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Transplant, Others

      1000 Participants Needed

      High-Dose Macitentan for PAH

      Omaha, Nebraska
      This trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Obesity, Diabetes, Hypertension, Coronary Artery Disease, Others

      935 Participants Needed

      Treprostinil for Pulmonary Arterial Hypertension

      Omaha, Nebraska
      The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Amphetamine Use, Hepatic Impairment, Others
      Must Be Taking:Endothelin Antagonists, PDE-5 Inhibitors

      52 Participants Needed

      Tadalafil for COPD with Pulmonary Hypertension

      Omaha, Nebraska
      This trial is testing whether tadalafil can help Veterans with COPD and high blood pressure in the lungs by reducing shortness of breath and improving overall health. The drug works by relaxing blood vessels to improve blood flow. The study will compare tadalafil to another group over several months to see if it makes a significant difference in symptoms and quality of life. Tadalafil received FDA approval in 2009 for the treatment of pulmonary arterial hypertension (PAH) and has shown to improve exercise capacity and quality of life in patients.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:35 - 89

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Systemic Hypotension, Hepatic Impairment, Renal Insufficiency, Others
      Must Be Taking:Long-acting Bronchodilators

      126 Participants Needed

      Nifedipine vs Enalapril for Postpartum Hypertension

      Omaha, Nebraska
      This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine. Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study. The only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:19+
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Contraindication To Medications, Heart Rate, Language

      850 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Hypertension clinical trials in Olathe, KS pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Hypertension clinical trials in Olathe, KS work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Hypertension trials in Olathe, KS 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Olathe, KS for Hypertension is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Olathe, KS several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Hypertension medical study in Olathe, KS?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Hypertension clinical trials in Olathe, KS?

      Most recently, we added Dapagliflozin + Baxdrostat for Chronic Kidney Disease, Reformulated PG324 for Glaucoma and AI Device for Pulmonary Hypertension in Interstitial Lung Disease to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Kansas

      Anxiety Clinical Trials in Kansas

      Schizophrenia Clinical Trials in Kansas

      ADHD Clinical Trials in Kansas

      Bipolar Disorder Clinical Trials in Kansas

      Multiple Sclerosis Clinical Trials in Kansas

      Autism Clinical Trials in Kansas

      Treatment Resistant Depression Clinical Trials in Kansas

      Borderline Personality Disorder Clinical Trials in Kansas

      Social Anxiety Disorder Clinical Trials in Kansas

      Parkinson's Disease Clinical Trials in Kansas

      Alzheimer's Disease Clinical Trials in Kansas

      By Location

      Clinical Trials near Wichita, KS

      Clinical Trials near Kansas City, KS

      Clinical Trials near Overland Park, KS

      Clinical Trials near Topeka, KS

      Clinical Trials near Westwood, KS

      Clinical Trials near Lenexa, KS

      Clinical Trials near Newton, KS

      Clinical Trials near Salina, KS

      Clinical Trials near Lawrence, KS

      Clinical Trials near El Dorado, KS

      Clinical Trials near Pratt, KS

      Clinical Trials near Wellington, KS

      Other People Viewed

      By Subject

      44 Hypertension Trials near Overland Park, KS

      55 Hypertension Trials near Houston, TX

      40 Hypertension Trials near Columbus, OH

      39 Hypertension Trials near Tampa, FL

      59 Hypertension Trials near Fort Lauderdale, FL

      215 Clinical Trials near El Dorado, KS

      142 Clinical Trials near Arkansas City, KS

      15 Depression Trials near Overland Park, KS

      Top Pulmonary Arterial Hypertension Clinical Trials

      Top Pulmonary Hypertension Clinical Trials

      Top Idiopathic Intracranial Hypertension Clinical Trials

      Top Hypertension Clinical Trials near Akron, OH

      By Trial

      Empagliflozin for Pulmonary Arterial Hypertension

      Riociguat + Treprostinil for Pulmonary Arterial Hypertension

      Riociguat for Pulmonary Hypertension Due to Heart Failure

      Oral Ifetroban for Scleroderma

      Noninvasive Ultrasound Technique for Portal Hypertension

      Pulse IVL for Peripheral Arterial Disease

      Angiotensin-(1-7) for Cardiovascular Health in Aging

      INZ-701 for Pseudoxanthoma Elasticum and Arterial Calcification

      Blood Pressure Treatment for High Blood Pressure

      Light Therapy and Exercise for PAD

      CardioCare Quest for High Blood Pressure

      Catheter-Directed Therapy for Post-Thrombotic Syndrome

      Related Searches

      Top Hypertension Clinical Trials near Overland Park, KS

      Top Hypertension Clinical Trials near Tampa, FL

      Top Depression Clinical Trials

      Top Clinical Trials near Florida

      Fenofibrate for Primary Sclerosing Cholangitis

      Opioid-Free Anesthesia for Opiate Dependence

      AIH for Spinal Cord Injury

      Nerve Block for Postoperative Shoulder Pain

      Cannabinoids + Anti-inflammatory Diet for Neuropathic Pain

      Medical Therapy for Myocardial Bridging

      Pazopanib for Renal Cell Carcinoma

      CPX-351 for Acute Myeloid Leukemia